Stock Movements, Declared Dividends, Financial Results, and Upcoming Investors Conferences - Analyst Notes on Mettler-Toledo, Sensata, Curtiss-Wright, Fluidigm and Ambarella

NEW YORK, May 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Mettler-Toledo International, Inc. (NYSE: MTD), Sensata Technologies Holding NV (NYSE: ST), Curtiss-Wright Corp. (NYSE: CW), Fluidigm Corporation (NASDAQ: FLDM) and Ambarella, Inc. (NASDAQ: AMBA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2529-100free.

--
Mettler-Toledo International, Inc. Analyst Notes
On May 9, 2014, Mettler-Toledo International, Inc.'s (Mettler-Toledo) stock increased 2.52%, ending the day at $241.79. Over the previous five trading sessions, shares in Mettler-Toledo increased 2.76%, compared to the Dow Jones Industrial Average which also increased 0.43% during the same period. The full analyst notes on Mettler-Toledo are available to download free of charge at:

http://www.analystsreview.com/2529-MTD-14May2014.pdf

--
Sensata Technologies Holding NV Analyst Notes
On May 9, 2014, Sensata Technologies Holding NV's (Sensata) stock declined 0.17%, ending the day at $41.70. Over the past one month, shares in Sensata declined 4.51%, compared to the Dow Jones Industrial Average which increased 2.01% during the same period. The full analyst notes on Sensata are available to download free of charge at:

http://www.analystsreview.com/2529-ST-14May2014.pdf

--
Curtiss-Wright Corp. Analyst Notes
On May 6, 2014, Curtiss-Wright Corp. (Curtiss-Wright) reported that the Board of Directors declared a dividend of $0.13 per share on Curtiss-Wright Common Stock. The dividend will be payable on July 10, 2014, to stockholders of record as of June 26, 2014. The full analyst notes on Curtiss-Wright are available to download free of charge at:

http://www.analystsreview.com/2529-CW-14May2014.pdf

--
Fluidigm Corporation Analyst Notes
On May 5, 2014, Fluidigm Corporation (Fluidigm) declared its Q1 2014 financial results. The Company's total revenue for Q1 2014 was $25.7 million, up 77.0% YoY. Q1 2014 net loss was $15.4 million or $0.57 per share, versus a net loss of $3.6 million or $0.14 per share in Q1 2013. Gajus Worthington, Fluidigm President and CEO, commented, "Our year-over-year revenue growth in the first quarter of 2014 was robust across our end markets and geographies. In the quarter, single-cell genomics revenue more than doubled year-over-year and the number of C1™ and BioMark™ unit sales motivated by single-cell research reached new records. We continue to enjoy a leadership position in this exciting, rapidly growing market. Meanwhile, utilization of our systems by our production genomics customers drove solid consumables pull-through." The Company expects 2014 total revenue to be between $111 million and $116 million. The full analyst notes on Fluidigm are available to download free of charge at:

http://www.analystsreview.com/2529-FLDM-14May2014.pdf

--
Ambarella, Inc. Analyst Notes
On May 6, 2014, Ambarella, Inc. (Ambarella) reported that it plans to host its Q1 FY2015 conference call on Tuesday, June 3, 2014, at 2:00 p.m. PT. Ambarella will also issue its earnings release after the market closing on the same day. The conference call will be webcast through the Company's investor page, and will also be archived for replay 30 minutes after the completion of the call. The full analyst notes on Ambarella are available to download free of charge at:

http://www.analystsreview.com/2529-AMBA-14May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review